Suggested remit: To appraise the clinical and cost effectiveness of durvalumab within its marketing authorisation for treating resectable gastric and gastro-oesophageal junction cancer.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Awaiting decision
- Process:
- STA Standard
- ID number:
- 6374
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email TACommB@nice.org.uk
Stakeholders
- Companies sponsors
- AstraZeneca (durvalumab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Stomach Cancer UK
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Comparator companies
- AS Kalceks (oxaliplatin) (not participating)
- Bristol-Myers Squibb (nivolumab) CAU received- Participating
- Hospira (docetaxel, fluorouracil, oxaliplatin) (not participating)
- Medac (fluorouracil, leucovorin, oxaliplatin) (not participating)
- Medac (leucovorin) (not participating)
- Ranbaxy (oxaliplatin) (not participating)
- Seacross Pharmaceuticals (docetaxel, oxaliplatin) (not participating)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 September 2025 | Invitation to participate |
| 16 July 2025 - 13 August 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 16 July 2025 | In progress. Scoping commenced. |
| 20 January 2025 | Note - Note added to the project documents |
| 23 December 2024 | Awaiting development. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early July 2025. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 21 June 2024 | Note - Note added to the project documents |
| 25 October 2023 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual